Esperion Therapeutics, Inc. Reports Third Quarter 2013 Financial Results and Provides Development Program Updates
Published: Nov 07, 2013
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today provided development program updates and reported its financial results for the third quarter ended September 30, 2013.
Help employers find you! Check out all the jobs and post your resume.